価格表

在庫・価格 : 2026年04月06日 06時36分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Cystic Fibrosis Air3Gel-96well (2 plates)
データシート※最新のデータシートでない場合があります
B3G-A3GCF-96W B3Gバックスリーゲル
Bac3Gel LDA
1 kit ¥96,000
(未発注)
追加

在庫・価格 : 2026年04月06日 06時36分 現在

Cystic Fibrosis Air3Gel-96well (2 plates)

  • 商品コード:B3G-A3GCF-96W
  • メーカー:B3G
  • 包装:1kit
  • 価格: ¥96,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Garbero OV et al. Tracing the path of Quorum sensing molecules in cystic fibrosis mucus in a biomimetic in vitro permeability platform. Sci Rep 2024 Oct;14(1):25907
Garbero OV et al
2024/01/01
PubMed
2 Butnarasu C et al. Permeability Assessment of a High-Throughput Mucosal Platform. Pharmaceutics 2023 Jan;15(2)
Butnarasu C et al
2023/01/01
PubMed
3 Davison MD et al. Identification of the sites in opsin modified by photoactivated azido[125I]iodobenzene. Biochem J 1986 Jun;236(2):389-95
Davison MD et al
1986/01/01
PubMed
4 Heterogeneity Governs 3D-Cultures of Clinically Relevant Microbial Communities.

PubMed
5 Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery.

PubMed
6 Butnarasu C et al. Mucin binding to therapeutic molecules: The case of antimicrobial agents used in cystic fibrosis. Int J Pharm 2019 Jun;564:136-144
Butnarasu C et al
2019/01/01
PubMed
7 Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies.

PubMed
8 Pedersoli L et al. Engineered modular microphysiological models of the human airway clearance phenomena. Biotechnol Bioeng 2021 Oct;118(10):3898-3913
Pedersoli L et al
2021/01/01
PubMed
9 Butnarasu C et al. Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform. Adv Healthc Mater 2022 Aug;11(15):e2200340
Butnarasu C et al
2022/01/01
PubMed
  • No.: 1
  • 文献情報:
    Garbero OV et al. Tracing the path of Quorum sensing molecules in cystic fibrosis mucus in a biomimetic in vitro permeability platform. Sci Rep 2024 Oct;14(1):25907
    Garbero OV et al
    2024/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Butnarasu C et al. Permeability Assessment of a High-Throughput Mucosal Platform. Pharmaceutics 2023 Jan;15(2)
    Butnarasu C et al
    2023/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Davison MD et al. Identification of the sites in opsin modified by photoactivated azido[125I]iodobenzene. Biochem J 1986 Jun;236(2):389-95
    Davison MD et al
    1986/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Heterogeneity Governs 3D-Cultures of Clinically Relevant Microbial Communities.

  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Disassembling the complexity of mucus barriers to develop a fast screening tool for early drug discovery.

  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Butnarasu C et al. Mucin binding to therapeutic molecules: The case of antimicrobial agents used in cystic fibrosis. Int J Pharm 2019 Jun;564:136-144
    Butnarasu C et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies.

  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Pedersoli L et al. Engineered modular microphysiological models of the human airway clearance phenomena. Biotechnol Bioeng 2021 Oct;118(10):3898-3913
    Pedersoli L et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Butnarasu C et al. Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform. Adv Healthc Mater 2022 Aug;11(15):e2200340
    Butnarasu C et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed